drugset
Drugs / CEA RNA-pulsed DC cancer vaccine
last change Jul 2002 re-read 3 minutes ago

CEA RNA-pulsed DC cancer vaccine

Vaccine

Developed for
bile duct cancer · breast cancer · colorectal cancer · gallbladder cancer · gastric cancer · head and neck cancer · lung cancer · malignant pancreatic neoplasm
+3 more · metastatic malignant neoplasm · ovarian cancer · testicular germ cell tumor
Investigated by
Duke University · National Cancer Institute (NCI)

Trials 1

today NCT00004604 · Ph 1
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00004604 Feb 1997 → Jun 2001 bile duct cancer, breast cancer, colorectal cancer, gallbladder cancer +7 Duke University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CEA RNA-pulsed DC cancer vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004604 ↗
Modality Vaccine “intravenous vaccine of autologous, cultured, dendritic cells pulsed with carcinoembryonic antigen (CEA) RNA” NCT00004604 ↗
Route Intravenous “intravenous vaccine of autologous, cultured, dendritic cells pulsed with carcinoembryonic antigen (CEA) RNA” NCT00004604 ↗